Earnings call transcript: Stevanato Group beats Q2 2025 earnings forecast, stock drops

Stevanato Group (STVN) reported Q2 2025 earnings exceeding analyst estimates with $0.11 EPS and $280 million revenue, an 8% year-over-year increase driven by robust growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and improved gross margins. Despite these strong financial results, the stock declined nearly 6% pre-market, reflecting investor concerns possibly related to its high 39.5x P/E valuation and a 2% revenue decrease in the Engineering segment. The company reiterated its full-year 2025 guidance, projecting continued high single-digit growth in BDS, fueled by demand for high-value solutions and biologics, while anticipating a low double-digit decline for Engineering.

Analysis

Stevanato Group (STVN) reported a solid second quarter for 2025, with revenue of $280 million and EPS of $0.11, surpassing analyst forecasts by 4.31% and 10% respectively. This top-line growth of 8% year-over-year was primarily fueled by a 10% expansion in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, where high-value solutions grew 13% and now account for 42% of total revenue. This favorable product mix, along with operational leverage at its newer facilities, contributed to a 210 basis point improvement in consolidated gross profit margin to 28.1%. Despite these positive results, the stock declined 5.98% pre-market, a reaction likely attributable to the persistent weakness in its Engineering segment and a high valuation. The Engineering segment's revenue fell 2%, and its full-year guidance was revised downward to a low double-digit decline, reflecting delays in new order intake. Management has reiterated its full-year 2025 guidance for revenue and adjusted EPS, indicating that the outperformance in the high-margin BDS segment is expected to fully offset both the Engineering segment's underperformance and headwinds from tariffs and foreign currency translation. The company noted it is mitigating the impact of increased U.S. tariffs through customer negotiations and optimizing its global manufacturing footprint, rather than absorbing a direct margin hit.

Key Decisions for Investors

• Investors should weigh the robust growth and margin expansion in the core Biopharmaceutical and Diagnostic Solutions (BDS) segment against the deteriorating outlook for the Engineering segment, as the investment thesis hinges on BDS's ability to continue offsetting this weakness.
• The negative stock reaction to an earnings beat suggests the market is sensitive to the company's high 39.5x P/E ratio; therefore, any position should account for the risk that the premium valuation requires flawless execution and a stronger outlook than was provided.
• Monitor for confirmation of delayed Engineering orders materializing in the second half of 2025 and the pace of margin improvement at the Latina and Fishers facilities, as these are critical factors for the company to meet its reiterated full-year guidance.
• Consider the stabilization of the vial market a key positive indicator, as management's confidence in a mid-to-high single-digit growth for the full year suggests a recovery from the significant destocking seen in the prior year.